v3.0.7
Please consider this website is continuously evolving and still under development
to harmonize automatic data extraction and integrate manual data annotation.
Column | Value |
---|---|
Trial registration number | EUCTR2022-000617-13-ES |
Full text link
Last imported at : April 19, 2022, 4 a.m. Source : EU Clinical Trials Register |
https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-000617-13/ES |
First author
Last imported at : April 19, 2022, 4 a.m. Source : EU Clinical Trials Register |
|
Contact
Last imported at : April 19, 2022, 4 a.m. Source : EU Clinical Trials Register |
obestard@vhebron.net |
Registration date
Last imported at : April 19, 2022, 4 a.m. Source : EU Clinical Trials Register |
2022-03-04 |
Recruitment status
Last imported at : June 11, 2024, 8 p.m. Source : EU Clinical Trials Register |
Completed |
Study design
Last imported at : April 19, 2022, 4 a.m. Source : EU Clinical Trials Register |
RCT |
Allocation
Last imported at : April 19, 2022, 4 a.m. Source : EU Clinical Trials Register |
Randomized |
Design
Last imported at : April 19, 2022, 4 a.m. Source : EU Clinical Trials Register |
Parallel |
Masking
Last imported at : April 19, 2022, 4 a.m. Source : EU Clinical Trials Register |
Open label |
Center
Last imported at : April 19, 2022, 4 a.m. Source : EU Clinical Trials Register |
multi-center |
Study aim
Last imported at : April 19, 2022, 4 a.m. Source : EU Clinical Trials Register |
Prevention |
Inclusion criteria
Last imported at : April 19, 2022, 4 a.m. Source : EU Clinical Trials Register |
1. Patient’s age ≥ 18 years 2. Time of transplantation ≥ 1 year 3. Negative or very weak (<143BAU/ml) serological immune response after 3 doses of an mRNA SARS-CoV-2 vaccine 4. Stable renal function with an estimated GFR ≥ 40 mL/min/1.73 m2 5. Urine protein to creatinine ratio < 0.8 g/g 6. Written informed consent 1. Edad del paciente ≥ 18 años 2. Tiempo de trasplante ≥ 1 año 3. Respuesta inmune serológica negativa o muy débil (<143BAU/ml) después de 3 dosis de una vacuna de ARNm SARS-CoV-2 4. Función renal estable con FG estimado ≥ 40 ml/min/1,73 m2 5. Proporción de proteína en orina a creatinina < 0,8 g/g 6. Consentimiento informado por escrito |
Exclusion criteria
Last imported at : April 19, 2022, 4 a.m. Source : EU Clinical Trials Register |
1. Previous diagnosis of T-cell mediated or antibody-mediated rejection 2. Previous seroconversion after any SARS-CoV-2 vaccine. 3. Previous COVID-19 infection 4. Presence of HLA donor-specific antibodies 5. Active cancer excluding non-melanoma skin cancer 6. Pregnancy 1. Diagnóstico previo de rechazo mediado por células T o mediado por anticuerpos 2. Seroconversión previa después de cualquier vacuna contra el SARS-CoV-2. 3. Infección previa por COVID-19 4. Presencia de anticuerpos específicos del donante HLA 5. Cáncer activo excluyendo el cáncer de piel no melanoma 6. Embarazo |
Number of arms
Last imported at : April 19, 2022, 4 a.m. Source : EU Clinical Trials Register |
2 |
Funding
Last imported at : April 19, 2022, 4 a.m. Source : EU Clinical Trials Register |
Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR) |
Inclusion age min
Last imported at : April 19, 2022, 4 a.m. Source : EU Clinical Trials Register |
18 |
Inclusion age max
Last imported at : April 19, 2022, 4 a.m. Source : EU Clinical Trials Register |
100 |
Countries
Last imported at : April 19, 2022, 4 a.m. Source : EU Clinical Trials Register |
Spain |
Type of patients
Last imported at : April 19, 2022, 4 a.m. Source : EU Clinical Trials Register |
High risk patients |
Severity scale
Last imported at : April 19, 2022, 4 a.m. Source : EU Clinical Trials Register |
N/A |
Total sample size
Last imported at : April 19, 2022, 4 a.m. Source : EU Clinical Trials Register |
50 |
primary outcome
Last imported at : April 19, 2022, 4 a.m. Source : EU Clinical Trials Register |
Difference in the percentage of patients with a positive humoral immune response one month after the 4th dose of the mRNA SARS-CoV-2 vaccine between groups. Diferencia en el porcentaje de pacientes con respuesta inmune humoral positiva al mes de la 4ª dosis de la vacuna mRNA SARS-CoV-2 entre grupos. |
Notes
Last imported at : April 19, 2022, 4 a.m. Source : EU Clinical Trials Register |
Declared number of arm (2.0) differs from found arms (3.0) |
Phase
Last imported at : April 19, 2022, 4 a.m. Source : EU Clinical Trials Register |
Phase 4 |
Arms
Last imported at : April 19, 2022, 4 a.m. Source : EU Clinical Trials Register |
[{"arm_notes": "New Type treatment : mycophenolate mofetil", "treatment_id": 2169, "treatment_name": "Mycophenolate mofetil", "treatment_type": "Immunosuppressants", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "New Type treatment : Sirolimus", "treatment_id": 1204, "treatment_name": "Sirolimus", "treatment_type": "Immunosuppressants", "pharmacological_treatment": "Pharmacological treatment"}] |